| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 104 | 2024 | 3451 | 6.850 |
Why?
|
| Blood Glucose | 132 | 2024 | 6375 | 4.680 |
Why?
|
| Hypoglycemic Agents | 65 | 2022 | 3149 | 4.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 147 | 2024 | 12281 | 4.200 |
Why?
|
| Insulin | 74 | 2023 | 6592 | 3.150 |
Why?
|
| Diabetes Complications | 27 | 2024 | 1342 | 2.770 |
Why?
|
| Diabetic Retinopathy | 33 | 2022 | 1268 | 2.750 |
Why?
|
| Diabetes Mellitus | 59 | 2023 | 5884 | 2.440 |
Why?
|
| Hyperglycemia | 29 | 2020 | 1380 | 2.250 |
Why?
|
| Blood Glucose Self-Monitoring | 23 | 2024 | 457 | 1.760 |
Why?
|
| Thiazolidinediones | 10 | 2015 | 465 | 1.500 |
Why?
|
| Metformin | 20 | 2023 | 912 | 1.290 |
Why?
|
| Life Style | 34 | 2024 | 3888 | 1.250 |
Why?
|
| Diabetic Nephropathies | 17 | 2024 | 988 | 1.160 |
Why?
|
| Blood Specimen Collection | 5 | 2021 | 238 | 1.080 |
Why?
|
| Cardiovascular Diseases | 39 | 2022 | 15740 | 1.020 |
Why?
|
| Insulin Resistance | 25 | 2018 | 3960 | 1.010 |
Why?
|
| Glucose Intolerance | 13 | 2020 | 579 | 1.010 |
Why?
|
| Hypoglycemia | 15 | 2021 | 888 | 0.990 |
Why?
|
| Insulin Infusion Systems | 17 | 2021 | 217 | 0.950 |
Why?
|
| Diabetic Angiopathies | 11 | 2016 | 822 | 0.920 |
Why?
|
| Serum Albumin | 3 | 2013 | 674 | 0.900 |
Why?
|
| Weight Loss | 17 | 2020 | 2683 | 0.820 |
Why?
|
| Pancreas, Artificial | 5 | 2014 | 54 | 0.800 |
Why?
|
| Postprandial Period | 6 | 2017 | 315 | 0.720 |
Why?
|
| Albuminuria | 11 | 2022 | 659 | 0.610 |
Why?
|
| Hematologic Tests | 1 | 2019 | 238 | 0.600 |
Why?
|
| Humans | 313 | 2024 | 760261 | 0.590 |
Why?
|
| Preventive Medicine | 1 | 2019 | 250 | 0.590 |
Why?
|
| Prediabetic State | 5 | 2022 | 550 | 0.570 |
Why?
|
| Glucagon | 5 | 2013 | 532 | 0.560 |
Why?
|
| Obesity | 31 | 2024 | 12915 | 0.530 |
Why?
|
| Clinical Trials as Topic | 13 | 2021 | 8058 | 0.470 |
Why?
|
| Adiponectin | 5 | 2012 | 1115 | 0.470 |
Why?
|
| Ramipril | 2 | 2019 | 97 | 0.440 |
Why?
|
| Adult | 124 | 2024 | 219847 | 0.420 |
Why?
|
| Male | 165 | 2024 | 359413 | 0.420 |
Why?
|
| Fasting | 17 | 2014 | 1603 | 0.420 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 4 | 2022 | 334 | 0.410 |
Why?
|
| alpha-MSH | 1 | 2012 | 71 | 0.410 |
Why?
|
| Follow-Up Studies | 35 | 2024 | 39254 | 0.410 |
Why?
|
| Middle Aged | 133 | 2024 | 220175 | 0.400 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2012 | 128 | 0.400 |
Why?
|
| Female | 173 | 2024 | 391011 | 0.400 |
Why?
|
| Glucose Tolerance Test | 16 | 2020 | 1174 | 0.400 |
Why?
|
| Tunica Media | 3 | 2011 | 112 | 0.400 |
Why?
|
| Exercise | 13 | 2022 | 5783 | 0.390 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2015 | 353 | 0.390 |
Why?
|
| Overweight | 10 | 2024 | 2421 | 0.390 |
Why?
|
| Cardiovascular System | 3 | 2021 | 850 | 0.380 |
Why?
|
| Disease Progression | 19 | 2024 | 13505 | 0.370 |
Why?
|
| Risk Factors | 74 | 2022 | 74269 | 0.370 |
Why?
|
| Diabetic Neuropathies | 9 | 2022 | 406 | 0.360 |
Why?
|
| History, 20th Century | 4 | 2024 | 2777 | 0.350 |
Why?
|
| Diet, Fat-Restricted | 3 | 2012 | 330 | 0.350 |
Why?
|
| Anti-Obesity Agents | 2 | 2012 | 229 | 0.350 |
Why?
|
| Injections, Subcutaneous | 5 | 2008 | 679 | 0.340 |
Why?
|
| Tunica Intima | 3 | 2011 | 459 | 0.340 |
Why?
|
| Cyclohexanes | 1 | 2010 | 152 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 15 | 2021 | 10340 | 0.340 |
Why?
|
| BCG Vaccine | 1 | 2012 | 371 | 0.330 |
Why?
|
| Monitoring, Physiologic | 13 | 2014 | 1784 | 0.330 |
Why?
|
| Pancreas Transplantation | 3 | 2003 | 196 | 0.320 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2008 | 1523 | 0.310 |
Why?
|
| Phenylalanine | 1 | 2010 | 365 | 0.310 |
Why?
|
| Valine | 1 | 2010 | 409 | 0.310 |
Why?
|
| Aged | 87 | 2024 | 168995 | 0.310 |
Why?
|
| Sulfonylurea Compounds | 6 | 2022 | 221 | 0.300 |
Why?
|
| Algorithms | 16 | 2017 | 13967 | 0.300 |
Why?
|
| Androgen Antagonists | 2 | 2008 | 1439 | 0.300 |
Why?
|
| Tosyl Compounds | 1 | 2008 | 112 | 0.300 |
Why?
|
| Glycosuria | 9 | 2011 | 44 | 0.290 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 2007 | 9 | 0.290 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 435 | 0.280 |
Why?
|
| Information Dissemination | 1 | 2015 | 1132 | 0.280 |
Why?
|
| Aging | 8 | 2020 | 8641 | 0.280 |
Why?
|
| Bariatric Surgery | 5 | 2017 | 1006 | 0.280 |
Why?
|
| Cholesterol, LDL | 7 | 2011 | 2422 | 0.280 |
Why?
|
| Reference Values | 12 | 2011 | 4920 | 0.270 |
Why?
|
| Disease Management | 8 | 2017 | 2508 | 0.270 |
Why?
|
| Hypercholesterolemia | 3 | 2002 | 1155 | 0.270 |
Why?
|
| Leuprolide | 1 | 2008 | 315 | 0.260 |
Why?
|
| Triazoles | 2 | 2013 | 904 | 0.260 |
Why?
|
| Dementia | 2 | 2018 | 2638 | 0.260 |
Why?
|
| Adipokines | 1 | 2008 | 311 | 0.260 |
Why?
|
| Adolescent | 41 | 2023 | 87747 | 0.260 |
Why?
|
| Pyrazines | 2 | 2013 | 1200 | 0.260 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 1208 | 0.250 |
Why?
|
| Glaucoma | 1 | 2015 | 1183 | 0.250 |
Why?
|
| History, 21st Century | 3 | 2021 | 1576 | 0.240 |
Why?
|
| Anilides | 1 | 2008 | 409 | 0.240 |
Why?
|
| Family Practice | 2 | 2007 | 512 | 0.240 |
Why?
|
| Tetrazoles | 1 | 2010 | 901 | 0.230 |
Why?
|
| Iron | 1 | 2012 | 1786 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 10 | 2020 | 7468 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 9 | 2020 | 5507 | 0.230 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 1156 | 0.220 |
Why?
|
| Peptides | 2 | 2012 | 4358 | 0.220 |
Why?
|
| Nutrition Therapy | 1 | 2004 | 102 | 0.220 |
Why?
|
| United States | 32 | 2023 | 72363 | 0.210 |
Why?
|
| Societies, Medical | 8 | 2016 | 3903 | 0.210 |
Why?
|
| Nitriles | 1 | 2008 | 955 | 0.210 |
Why?
|
| Specialization | 2 | 2007 | 779 | 0.210 |
Why?
|
| Infusion Pumps, Implantable | 4 | 1997 | 157 | 0.210 |
Why?
|
| Kidney Failure, Chronic | 2 | 2012 | 2469 | 0.210 |
Why?
|
| Glomerular Filtration Rate | 3 | 2024 | 2178 | 0.210 |
Why?
|
| Musculoskeletal Diseases | 2 | 2014 | 594 | 0.210 |
Why?
|
| Diabetic Cardiomyopathies | 2 | 2014 | 96 | 0.210 |
Why?
|
| Carotid Artery, Common | 1 | 2003 | 177 | 0.200 |
Why?
|
| Evidence-Based Medicine | 9 | 2017 | 3696 | 0.200 |
Why?
|
| Incidence | 17 | 2023 | 21378 | 0.200 |
Why?
|
| Body Composition | 4 | 2015 | 2418 | 0.200 |
Why?
|
| Triglycerides | 11 | 2011 | 2476 | 0.200 |
Why?
|
| Drug Therapy, Combination | 7 | 2022 | 6499 | 0.200 |
Why?
|
| Diabetes, Gestational | 5 | 2020 | 1241 | 0.200 |
Why?
|
| Young Adult | 25 | 2022 | 58673 | 0.200 |
Why?
|
| Dietary Services | 1 | 2001 | 17 | 0.200 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2003 | 191 | 0.190 |
Why?
|
| Europe | 5 | 2012 | 3433 | 0.190 |
Why?
|
| Body Mass Index | 22 | 2017 | 12901 | 0.190 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2021 | 26 | 0.190 |
Why?
|
| Glycoproteins | 2 | 2007 | 2208 | 0.180 |
Why?
|
| Attitude to Health | 2 | 2015 | 2028 | 0.180 |
Why?
|
| Medicine | 3 | 2009 | 943 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 1521 | 0.170 |
Why?
|
| Shoulder | 1 | 2002 | 299 | 0.170 |
Why?
|
| Regression Analysis | 11 | 2010 | 6361 | 0.170 |
Why?
|
| Mass Screening | 6 | 2017 | 5422 | 0.170 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2006 | 1153 | 0.170 |
Why?
|
| Monitoring, Ambulatory | 4 | 2011 | 353 | 0.170 |
Why?
|
| Drug Approval | 1 | 2007 | 816 | 0.170 |
Why?
|
| Glucagon-Like Peptide 1 | 3 | 2013 | 366 | 0.170 |
Why?
|
| Capillaries | 3 | 2021 | 745 | 0.170 |
Why?
|
| Longitudinal Studies | 13 | 2020 | 14482 | 0.170 |
Why?
|
| Treatment Outcome | 22 | 2022 | 64947 | 0.170 |
Why?
|
| Glyburide | 3 | 2006 | 114 | 0.160 |
Why?
|
| Carbohydrate Metabolism | 1 | 2020 | 262 | 0.160 |
Why?
|
| Risk Reduction Behavior | 4 | 2024 | 1109 | 0.160 |
Why?
|
| Patient Satisfaction | 2 | 2002 | 3451 | 0.160 |
Why?
|
| Lipoproteins, LDL | 3 | 2010 | 641 | 0.160 |
Why?
|
| Antigen-Antibody Complex | 2 | 2010 | 513 | 0.160 |
Why?
|
| Hemoglobin A | 4 | 1983 | 84 | 0.160 |
Why?
|
| Coronary Disease | 8 | 2010 | 5993 | 0.160 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2021 | 787 | 0.150 |
Why?
|
| Glucose | 5 | 2023 | 4361 | 0.150 |
Why?
|
| Time Factors | 24 | 2017 | 40133 | 0.150 |
Why?
|
| Microcirculation | 3 | 2019 | 1279 | 0.150 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2008 | 186 | 0.150 |
Why?
|
| Drug Administration Schedule | 6 | 2015 | 4900 | 0.150 |
Why?
|
| Endocrinology | 2 | 2016 | 442 | 0.150 |
Why?
|
| Proportional Hazards Models | 12 | 2017 | 12532 | 0.150 |
Why?
|
| Comparative Effectiveness Research | 3 | 2022 | 718 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2004 | 389 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2002 | 730 | 0.140 |
Why?
|
| Patient Education as Topic | 7 | 2017 | 2311 | 0.140 |
Why?
|
| Case-Control Studies | 13 | 2015 | 22041 | 0.140 |
Why?
|
| Prevalence | 16 | 2017 | 15687 | 0.140 |
Why?
|
| Hand | 1 | 2002 | 903 | 0.140 |
Why?
|
| Analysis of Variance | 6 | 2010 | 6242 | 0.140 |
Why?
|
| Glucagon-Like Peptides | 2 | 2015 | 159 | 0.140 |
Why?
|
| Placebos | 3 | 2012 | 1672 | 0.130 |
Why?
|
| Carotid Arteries | 2 | 2011 | 951 | 0.130 |
Why?
|
| Physicians, Family | 2 | 2009 | 349 | 0.130 |
Why?
|
| Sodium-Glucose Transport Proteins | 1 | 2015 | 13 | 0.130 |
Why?
|
| Chromans | 2 | 2007 | 117 | 0.130 |
Why?
|
| Vitamin D | 3 | 2015 | 3293 | 0.130 |
Why?
|
| Lipids | 7 | 2010 | 3336 | 0.130 |
Why?
|
| Insulin-Secreting Cells | 4 | 2012 | 907 | 0.130 |
Why?
|
| Ketone Bodies | 2 | 2011 | 76 | 0.130 |
Why?
|
| Islets of Langerhans | 2 | 2012 | 1341 | 0.130 |
Why?
|
| Myocardial Infarction | 5 | 2022 | 11891 | 0.120 |
Why?
|
| Risk | 10 | 2014 | 9629 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2012 | 4357 | 0.120 |
Why?
|
| Hyperinsulinism | 5 | 2001 | 398 | 0.120 |
Why?
|
| Connecticut | 1 | 2015 | 364 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2012 | 15766 | 0.120 |
Why?
|
| Cohort Studies | 22 | 2023 | 41317 | 0.120 |
Why?
|
| Body Weight | 6 | 2015 | 4613 | 0.120 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 58947 | 0.110 |
Why?
|
| Sex Factors | 9 | 2014 | 10530 | 0.110 |
Why?
|
| Prostatic Neoplasms | 2 | 2008 | 11341 | 0.110 |
Why?
|
| Physical Fitness | 2 | 2016 | 732 | 0.110 |
Why?
|
| C-Peptide | 3 | 2012 | 433 | 0.110 |
Why?
|
| Empirical Research | 1 | 2014 | 120 | 0.110 |
Why?
|
| Massachusetts | 13 | 2020 | 8805 | 0.110 |
Why?
|
| Receptors, Gastrointestinal Hormone | 2 | 2010 | 39 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 2008 | 1549 | 0.110 |
Why?
|
| Calcinosis | 4 | 2014 | 1478 | 0.110 |
Why?
|
| Insulin, Long-Acting | 1 | 2013 | 58 | 0.110 |
Why?
|
| Postpartum Period | 1 | 2020 | 1168 | 0.110 |
Why?
|
| Gastroparesis | 1 | 2015 | 137 | 0.110 |
Why?
|
| Cholesterol, HDL | 7 | 2022 | 1817 | 0.110 |
Why?
|
| Autoantibodies | 2 | 2012 | 2119 | 0.110 |
Why?
|
| Prospective Studies | 20 | 2018 | 54263 | 0.110 |
Why?
|
| Macular Edema | 1 | 2017 | 375 | 0.110 |
Why?
|
| Retina | 3 | 2017 | 2635 | 0.110 |
Why?
|
| Genome-Wide Association Study | 9 | 2012 | 12602 | 0.110 |
Why?
|
| Gastric Emptying | 1 | 2015 | 243 | 0.110 |
Why?
|
| Self Report | 2 | 2022 | 3707 | 0.100 |
Why?
|
| Hashimoto Disease | 1 | 2014 | 105 | 0.100 |
Why?
|
| Quality of Life | 6 | 2014 | 13300 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2023 | 2093 | 0.100 |
Why?
|
| Genetic Loci | 3 | 2010 | 2618 | 0.100 |
Why?
|
| Vitrectomy | 1 | 2015 | 388 | 0.100 |
Why?
|
| Genetic Variation | 4 | 2011 | 6540 | 0.100 |
Why?
|
| Weight Gain | 4 | 2009 | 2347 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2021 | 9283 | 0.100 |
Why?
|
| Glutamate Decarboxylase | 1 | 2012 | 239 | 0.100 |
Why?
|
| Erythrocytes | 2 | 2016 | 2415 | 0.100 |
Why?
|
| Primary Health Care | 4 | 2012 | 4649 | 0.100 |
Why?
|
| Atherosclerosis | 3 | 2019 | 3524 | 0.100 |
Why?
|
| Diet, Reducing | 2 | 2013 | 487 | 0.100 |
Why?
|
| Fructosamine | 1 | 2010 | 14 | 0.090 |
Why?
|
| Angiopoietins | 1 | 2011 | 85 | 0.090 |
Why?
|
| Resistin | 2 | 2009 | 172 | 0.090 |
Why?
|
| Brain | 1 | 2018 | 26912 | 0.090 |
Why?
|
| Glycosides | 2 | 1981 | 112 | 0.090 |
Why?
|
| Cataract Extraction | 1 | 2015 | 466 | 0.090 |
Why?
|
| Internet | 1 | 2003 | 3074 | 0.090 |
Why?
|
| Glycosylation | 3 | 2010 | 1097 | 0.090 |
Why?
|
| Kinetics | 4 | 2016 | 6378 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 2852 | 0.090 |
Why?
|
| Double-Blind Method | 6 | 2012 | 12412 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 1416 | 0.090 |
Why?
|
| TCF Transcription Factors | 2 | 2010 | 138 | 0.090 |
Why?
|
| Research Personnel | 1 | 2015 | 584 | 0.090 |
Why?
|
| Joint Diseases | 1 | 2014 | 458 | 0.090 |
Why?
|
| Inflammation | 3 | 2008 | 10757 | 0.090 |
Why?
|
| Prognosis | 6 | 2024 | 29636 | 0.090 |
Why?
|
| Blood Pressure | 9 | 2011 | 8523 | 0.090 |
Why?
|
| Extracellular Fluid | 1 | 2011 | 165 | 0.090 |
Why?
|
| Brain Concussion | 1 | 2021 | 1394 | 0.080 |
Why?
|
| Health Services | 1 | 2014 | 754 | 0.080 |
Why?
|
| Health Surveys | 3 | 2008 | 4061 | 0.080 |
Why?
|
| Self Care | 4 | 2007 | 793 | 0.080 |
Why?
|
| Cataract | 1 | 2015 | 828 | 0.080 |
Why?
|
| Genetic Testing | 3 | 2011 | 3530 | 0.080 |
Why?
|
| Linear Models | 5 | 2015 | 5876 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 5 | 2012 | 1375 | 0.080 |
Why?
|
| Tryptophan | 1 | 2010 | 480 | 0.080 |
Why?
|
| Hexokinase | 1 | 2008 | 125 | 0.080 |
Why?
|
| Obesity, Morbid | 2 | 2016 | 1287 | 0.080 |
Why?
|
| Reproducibility of Results | 8 | 2014 | 20048 | 0.080 |
Why?
|
| Inpatients | 3 | 2012 | 2578 | 0.080 |
Why?
|
| Infusion Pumps | 1 | 2008 | 163 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2002 | 3159 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 10829 | 0.070 |
Why?
|
| Databases, Factual | 4 | 2021 | 8018 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2009 | 346 | 0.070 |
Why?
|
| Coronary Artery Disease | 4 | 2010 | 6661 | 0.070 |
Why?
|
| Cross-Sectional Studies | 14 | 2015 | 25928 | 0.070 |
Why?
|
| Dyslipidemias | 3 | 2022 | 895 | 0.070 |
Why?
|
| Exercise Therapy | 2 | 2015 | 920 | 0.070 |
Why?
|
| Baltimore | 2 | 2004 | 230 | 0.070 |
Why?
|
| Receptors, Drug | 1 | 2007 | 157 | 0.070 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2007 | 91 | 0.070 |
Why?
|
| Arginine | 1 | 2010 | 934 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 5 | 1991 | 1628 | 0.070 |
Why?
|
| Age of Onset | 2 | 2011 | 3302 | 0.070 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 1075 | 0.070 |
Why?
|
| Amino Acid Substitution | 2 | 2011 | 1737 | 0.070 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2006 | 52 | 0.070 |
Why?
|
| Immunity, Humoral | 1 | 2010 | 604 | 0.070 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2007 | 144 | 0.070 |
Why?
|
| Critical Pathways | 1 | 2009 | 475 | 0.070 |
Why?
|
| Heart Failure | 3 | 2022 | 11835 | 0.070 |
Why?
|
| Dietary Carbohydrates | 2 | 2008 | 893 | 0.060 |
Why?
|
| Adipose Tissue | 2 | 2009 | 3293 | 0.060 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 749 | 0.060 |
Why?
|
| Metabolomics | 1 | 2015 | 1626 | 0.060 |
Why?
|
| Leadership | 1 | 2015 | 1372 | 0.060 |
Why?
|
| Menopause | 1 | 2013 | 1640 | 0.060 |
Why?
|
| Cortisone | 1 | 1985 | 87 | 0.060 |
Why?
|
| Logistic Models | 10 | 2017 | 13311 | 0.060 |
Why?
|
| Pregnancy | 6 | 2020 | 29725 | 0.060 |
Why?
|
| Models, Biological | 4 | 2016 | 9468 | 0.060 |
Why?
|
| Absorptiometry, Photon | 2 | 2015 | 1731 | 0.060 |
Why?
|
| Fractures, Bone | 1 | 2017 | 2041 | 0.060 |
Why?
|
| Depressive Disorder | 2 | 2008 | 3728 | 0.060 |
Why?
|
| Emergency Service, Hospital | 3 | 2013 | 7809 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2011 | 1521 | 0.060 |
Why?
|
| Ice Cream | 1 | 1984 | 4 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2011 | 2608 | 0.060 |
Why?
|
| Urine | 1 | 1986 | 363 | 0.060 |
Why?
|
| Verbal Learning | 1 | 1987 | 462 | 0.060 |
Why?
|
| Health Care Costs | 2 | 2016 | 3257 | 0.060 |
Why?
|
| Caloric Restriction | 2 | 2018 | 295 | 0.060 |
Why?
|
| Health Behavior | 2 | 2015 | 2621 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2009 | 1218 | 0.060 |
Why?
|
| Gender Identity | 1 | 2010 | 699 | 0.060 |
Why?
|
| Autoimmunity | 1 | 2012 | 1370 | 0.060 |
Why?
|
| Least-Squares Analysis | 2 | 2003 | 369 | 0.060 |
Why?
|
| Potassium Channels | 1 | 2007 | 532 | 0.060 |
Why?
|
| Creatinine | 5 | 2001 | 1906 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2007 | 484 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14656 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 563 | 0.060 |
Why?
|
| Hypertension | 9 | 2022 | 8595 | 0.060 |
Why?
|
| Physicians | 3 | 2015 | 4590 | 0.050 |
Why?
|
| Anthropometry | 2 | 2006 | 1348 | 0.050 |
Why?
|
| Homeostasis | 3 | 2010 | 3305 | 0.050 |
Why?
|
| Costa Rica | 1 | 2003 | 177 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1984 | 238 | 0.050 |
Why?
|
| Ultrasonography | 4 | 2014 | 5960 | 0.050 |
Why?
|
| Physical Exertion | 1 | 1985 | 662 | 0.050 |
Why?
|
| Lysine | 1 | 2007 | 1002 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 6 | 2004 | 2178 | 0.050 |
Why?
|
| Tenosynovitis | 1 | 2002 | 57 | 0.050 |
Why?
|
| Models, Theoretical | 2 | 2017 | 3561 | 0.050 |
Why?
|
| Hemostasis | 2 | 2006 | 468 | 0.050 |
Why?
|
| Employment | 1 | 2008 | 1111 | 0.050 |
Why?
|
| Adenoma, Islet Cell | 1 | 1981 | 72 | 0.050 |
Why?
|
| Bursitis | 1 | 2002 | 80 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2002 | 277 | 0.050 |
Why?
|
| Apolipoproteins E | 2 | 2013 | 1437 | 0.050 |
Why?
|
| C-Reactive Protein | 3 | 2008 | 3822 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 10552 | 0.050 |
Why?
|
| Dupuytren Contracture | 1 | 2002 | 66 | 0.050 |
Why?
|
| Photography | 2 | 2017 | 530 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2007 | 817 | 0.050 |
Why?
|
| Waist Circumference | 2 | 2015 | 922 | 0.050 |
Why?
|
| Minority Groups | 1 | 2008 | 1199 | 0.050 |
Why?
|
| Research Design | 3 | 2019 | 6181 | 0.050 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2003 | 546 | 0.050 |
Why?
|
| Coronary Stenosis | 1 | 2006 | 820 | 0.040 |
Why?
|
| Multivariate Analysis | 7 | 2009 | 12156 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 15827 | 0.040 |
Why?
|
| Alleles | 5 | 2011 | 6900 | 0.040 |
Why?
|
| Predictive Value of Tests | 7 | 2010 | 15273 | 0.040 |
Why?
|
| Risk Assessment | 6 | 2019 | 24086 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2011 | 3466 | 0.040 |
Why?
|
| Albumins | 1 | 2022 | 577 | 0.040 |
Why?
|
| Forecasting | 1 | 2009 | 2931 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2009 | 1940 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2001 | 437 | 0.040 |
Why?
|
| Infusions, Intravenous | 4 | 1997 | 2235 | 0.040 |
Why?
|
| Imidazolidines | 1 | 1999 | 38 | 0.040 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 2296 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2003 | 725 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2014 | 1577 | 0.040 |
Why?
|
| Boston | 6 | 2012 | 9282 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2011 | 5073 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2014 | 2698 | 0.040 |
Why?
|
| Evoked Potentials, Visual | 1 | 2001 | 415 | 0.040 |
Why?
|
| Age Factors | 4 | 2009 | 18415 | 0.040 |
Why?
|
| Retrospective Studies | 8 | 2024 | 80301 | 0.040 |
Why?
|
| Kidney Transplantation | 2 | 1991 | 4215 | 0.040 |
Why?
|
| Medical Staff, Hospital | 1 | 2003 | 600 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 1064 | 0.040 |
Why?
|
| Hospitalization | 2 | 2012 | 10761 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 2218 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2007 | 5120 | 0.040 |
Why?
|
| Dietary Fats | 2 | 2008 | 1992 | 0.040 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2002 | 303 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2013 | 3327 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2006 | 1207 | 0.040 |
Why?
|
| Cholesterol | 5 | 2004 | 2925 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 1675 | 0.040 |
Why?
|
| Phenazopyridine | 1 | 1977 | 4 | 0.040 |
Why?
|
| Microvessels | 1 | 2022 | 572 | 0.040 |
Why?
|
| Homocysteine | 1 | 2001 | 640 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2012 | 17766 | 0.040 |
Why?
|
| Internationality | 2 | 2016 | 1005 | 0.040 |
Why?
|
| Genotype | 5 | 2013 | 12959 | 0.040 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 2 | 2010 | 152 | 0.040 |
Why?
|
| Methemoglobinemia | 1 | 1977 | 43 | 0.040 |
Why?
|
| Delivery of Health Care | 2 | 2003 | 5324 | 0.040 |
Why?
|
| Patient Selection | 4 | 2016 | 4276 | 0.040 |
Why?
|
| Testosterone | 2 | 2006 | 2469 | 0.040 |
Why?
|
| Blood Coagulation Factors | 1 | 2000 | 366 | 0.040 |
Why?
|
| Behavior Therapy | 2 | 2015 | 869 | 0.040 |
Why?
|
| Kidney | 1 | 1993 | 7072 | 0.040 |
Why?
|
| Visual Acuity | 3 | 2017 | 2635 | 0.040 |
Why?
|
| Visual Pathways | 1 | 2001 | 534 | 0.040 |
Why?
|
| Eating | 2 | 1996 | 1538 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2007 | 4169 | 0.040 |
Why?
|
| Macular Degeneration | 1 | 2004 | 1003 | 0.040 |
Why?
|
| Trisaccharides | 1 | 1996 | 49 | 0.040 |
Why?
|
| Pilot Projects | 3 | 2015 | 8553 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 2003 | 881 | 0.030 |
Why?
|
| Endothelium, Vascular | 2 | 2006 | 4437 | 0.030 |
Why?
|
| Thyroiditis, Autoimmune | 2 | 2014 | 101 | 0.030 |
Why?
|
| Anemia, Hemolytic | 1 | 1977 | 163 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2017 | 314 | 0.030 |
Why?
|
| Consensus | 2 | 2016 | 3106 | 0.030 |
Why?
|
| Gene Frequency | 3 | 2009 | 3605 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2013 | 2646 | 0.030 |
Why?
|
| Depression | 2 | 2014 | 8033 | 0.030 |
Why?
|
| Pregnancy Trimester, First | 2 | 2015 | 909 | 0.030 |
Why?
|
| Circadian Rhythm | 3 | 2014 | 2567 | 0.030 |
Why?
|
| Feedback | 1 | 1999 | 791 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1996 | 361 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2012 | 10183 | 0.030 |
Why?
|
| Hand Strength | 1 | 2018 | 452 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 1996 | 413 | 0.030 |
Why?
|
| Smoking | 4 | 2013 | 9070 | 0.030 |
Why?
|
| Social Class | 1 | 2004 | 2005 | 0.030 |
Why?
|
| Teaching Rounds | 1 | 2019 | 275 | 0.030 |
Why?
|
| Gestational Age | 2 | 2020 | 3564 | 0.030 |
Why?
|
| Adiposity | 2 | 2015 | 1851 | 0.030 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2015 | 91 | 0.030 |
Why?
|
| Bionics | 1 | 2014 | 46 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 4286 | 0.030 |
Why?
|
| Recurrence | 1 | 2006 | 8487 | 0.030 |
Why?
|
| Medical Records | 2 | 2012 | 1407 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 3381 | 0.030 |
Why?
|
| Bayes Theorem | 2 | 2013 | 2325 | 0.030 |
Why?
|
| Anticholesteremic Agents | 1 | 2001 | 988 | 0.030 |
Why?
|
| Random Allocation | 2 | 1989 | 2394 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2001 | 1084 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 1724 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2016 | 385 | 0.030 |
Why?
|
| Neoplasms | 2 | 2020 | 22066 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 971 | 0.030 |
Why?
|
| Statistics as Topic | 3 | 2008 | 2363 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2009 | 3421 | 0.030 |
Why?
|
| Registries | 3 | 2021 | 8449 | 0.030 |
Why?
|
| Acute Disease | 1 | 2003 | 7268 | 0.030 |
Why?
|
| Electrophoresis, Agar Gel | 2 | 1984 | 217 | 0.030 |
Why?
|
| Physician's Role | 1 | 1999 | 920 | 0.030 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2009 | 257 | 0.030 |
Why?
|
| Feeding Behavior | 2 | 2002 | 3185 | 0.030 |
Why?
|
| Genes, MHC Class I | 1 | 1993 | 240 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2004 | 2510 | 0.030 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2015 | 263 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2009 | 4763 | 0.030 |
Why?
|
| Semicarbazides | 2 | 1982 | 2 | 0.030 |
Why?
|
| Motivation | 3 | 2009 | 1990 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2008 | 968 | 0.030 |
Why?
|
| Rural Population | 1 | 2003 | 2267 | 0.030 |
Why?
|
| Proinsulin | 1 | 1992 | 135 | 0.020 |
Why?
|
| Isoelectric Focusing | 2 | 2000 | 160 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2005 | 2809 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 163 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2012 | 169 | 0.020 |
Why?
|
| Texas | 2 | 2003 | 401 | 0.020 |
Why?
|
| Hospitals, Teaching | 2 | 1994 | 1166 | 0.020 |
Why?
|
| Guidelines as Topic | 2 | 2010 | 1395 | 0.020 |
Why?
|
| Cognition | 2 | 1988 | 6948 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 987 | 0.020 |
Why?
|
| Infusions, Subcutaneous | 1 | 2010 | 43 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 2010 | 112 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2012 | 516 | 0.020 |
Why?
|
| Aspirin | 1 | 1983 | 3365 | 0.020 |
Why?
|
| Diet | 1 | 2008 | 8008 | 0.020 |
Why?
|
| Depth Perception | 1 | 1991 | 94 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 8551 | 0.020 |
Why?
|
| Memory | 1 | 2020 | 2179 | 0.020 |
Why?
|
| Intra-Abdominal Fat | 1 | 2015 | 607 | 0.020 |
Why?
|
| Remission Induction | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Ophthalmoscopy | 1 | 1991 | 171 | 0.020 |
Why?
|
| Infusions, Parenteral | 2 | 1997 | 404 | 0.020 |
Why?
|
| Aftercare | 1 | 2016 | 918 | 0.020 |
Why?
|
| Animals | 5 | 2012 | 167940 | 0.020 |
Why?
|
| Fatty Acid Desaturases | 1 | 2010 | 102 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2013 | 1375 | 0.020 |
Why?
|
| Health Education | 1 | 2016 | 1049 | 0.020 |
Why?
|
| Decision Making | 1 | 2003 | 3924 | 0.020 |
Why?
|
| Urban Health | 1 | 2012 | 533 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2016 | 1478 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1995 | 1723 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2017 | 2656 | 0.020 |
Why?
|
| Seasons | 1 | 2015 | 1523 | 0.020 |
Why?
|
| Fundus Oculi | 1 | 1991 | 541 | 0.020 |
Why?
|
| Proteins | 2 | 2010 | 6030 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2019 | 2283 | 0.020 |
Why?
|
| Incretins | 1 | 2010 | 103 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 1500 | 0.020 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 2008 | 114 | 0.020 |
Why?
|
| Cause of Death | 2 | 2015 | 3723 | 0.020 |
Why?
|
| Perceptual Disorders | 1 | 1991 | 197 | 0.020 |
Why?
|
| Outpatients | 3 | 2004 | 1606 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 1994 | 664 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 2061 | 0.020 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 2753 | 0.020 |
Why?
|
| Antihypertensive Agents | 2 | 2010 | 2063 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1996 | 1876 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 2192 | 0.020 |
Why?
|
| Intelligence Tests | 2 | 1988 | 498 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 788 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 759 | 0.020 |
Why?
|
| Professional Practice | 1 | 2009 | 313 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2007 | 239 | 0.020 |
Why?
|
| Sick Role | 1 | 1988 | 230 | 0.020 |
Why?
|
| Privacy | 1 | 2009 | 233 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2016 | 2255 | 0.020 |
Why?
|
| Social Support | 1 | 2017 | 2145 | 0.020 |
Why?
|
| Pregnancy in Diabetics | 1 | 1988 | 194 | 0.020 |
Why?
|
| Length of Stay | 3 | 2013 | 6472 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2010 | 540 | 0.020 |
Why?
|
| Language Tests | 1 | 1987 | 190 | 0.020 |
Why?
|
| Child | 4 | 2021 | 79758 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 667 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2014 | 1826 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1993 | 1354 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1786 | 0.020 |
Why?
|
| Aniline Compounds | 2 | 1982 | 1068 | 0.020 |
Why?
|
| Language Disorders | 1 | 1987 | 139 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2009 | 488 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 1989 | 409 | 0.020 |
Why?
|
| Suspensions | 1 | 1985 | 66 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 584 | 0.020 |
Why?
|
| Genome, Human | 2 | 2009 | 4416 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 694 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1992 | 1207 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2010 | 795 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2010 | 1975 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 2512 | 0.020 |
Why?
|
| Pyridines | 1 | 1977 | 2877 | 0.020 |
Why?
|
| Cicatrix | 1 | 2011 | 781 | 0.020 |
Why?
|
| Enteroendocrine Cells | 1 | 2006 | 77 | 0.020 |
Why?
|
| Psychological Tests | 1 | 1988 | 639 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2012 | 10185 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 680 | 0.020 |
Why?
|
| Citrus | 1 | 1985 | 44 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1993 | 2612 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1991 | 1679 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 1989 | 969 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2006 | 280 | 0.020 |
Why?
|
| Blood Proteins | 2 | 2004 | 1172 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 1128 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2009 | 1181 | 0.010 |
Why?
|
| Autoanalysis | 1 | 1984 | 71 | 0.010 |
Why?
|
| Nursing Assessment | 1 | 2004 | 106 | 0.010 |
Why?
|
| Ophthalmology | 1 | 1991 | 549 | 0.010 |
Why?
|
| Body Size | 1 | 2007 | 462 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2016 | 2155 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 36247 | 0.010 |
Why?
|
| Canada | 1 | 2009 | 2128 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 820 | 0.010 |
Why?
|
| Suicide | 1 | 2015 | 1599 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2009 | 966 | 0.010 |
Why?
|
| Postmenopause | 1 | 1992 | 2503 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1981 | 5333 | 0.010 |
Why?
|
| Ketones | 1 | 2004 | 183 | 0.010 |
Why?
|
| Sex Characteristics | 2 | 2005 | 2627 | 0.010 |
Why?
|
| Hemoglobinometry | 1 | 2002 | 35 | 0.010 |
Why?
|
| Erectile Dysfunction | 1 | 1986 | 452 | 0.010 |
Why?
|
| Perception | 1 | 2009 | 1194 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2010 | 1739 | 0.010 |
Why?
|
| Patients | 1 | 2009 | 906 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1991 | 1180 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6545 | 0.010 |
Why?
|
| Age Distribution | 1 | 2008 | 2893 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1987 | 708 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 1880 | 0.010 |
Why?
|
| Milk | 1 | 1985 | 443 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 4625 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2014 | 2889 | 0.010 |
Why?
|
| Self Efficacy | 1 | 2006 | 629 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 2006 | 673 | 0.010 |
Why?
|
| Retinal Vessels | 1 | 2007 | 836 | 0.010 |
Why?
|
| Blood Protein Electrophoresis | 1 | 1981 | 71 | 0.010 |
Why?
|
| Odds Ratio | 2 | 2005 | 9712 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 11902 | 0.010 |
Why?
|
| Patient Compliance | 2 | 2002 | 2689 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2010 | 2101 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1992 | 5201 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 1996 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2021 | 6797 | 0.010 |
Why?
|
| Haplotypes | 1 | 2007 | 2764 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 2696 | 0.010 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 2008 | 0.010 |
Why?
|
| Health Status | 1 | 1994 | 4081 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 2008 | 1727 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1993 | 2250 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1983 | 1388 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 2414 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1983 | 956 | 0.010 |
Why?
|
| Hypolipidemic Agents | 1 | 2005 | 626 | 0.010 |
Why?
|
| Bulimia | 1 | 2002 | 399 | 0.010 |
Why?
|
| Acetylation | 1 | 1983 | 1062 | 0.010 |
Why?
|
| Data Collection | 1 | 2009 | 3317 | 0.010 |
Why?
|
| Contrast Sensitivity | 1 | 2001 | 235 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 2804 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 2000 | 124 | 0.010 |
Why?
|
| Beverages | 1 | 1985 | 819 | 0.010 |
Why?
|
| Aldehyde Reductase | 1 | 1999 | 71 | 0.010 |
Why?
|
| ROC Curve | 1 | 2007 | 3568 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2012 | 3475 | 0.010 |
Why?
|
| Lipoproteins, VLDL | 1 | 2000 | 201 | 0.010 |
Why?
|
| Gene Expression | 1 | 2012 | 7592 | 0.010 |
Why?
|
| Exercise Test | 1 | 2007 | 2125 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 2476 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 782 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2010 | 4560 | 0.010 |
Why?
|
| Myocardium | 1 | 2011 | 4688 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2006 | 1395 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 2000 | 332 | 0.010 |
Why?
|
| Family Health | 1 | 2003 | 1258 | 0.010 |
Why?
|
| Vitamin B 12 | 1 | 2001 | 522 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2001 | 670 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1991 | 4423 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1991 | 3598 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2007 | 2563 | 0.010 |
Why?
|
| Health Resources | 1 | 2004 | 936 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2001 | 1635 | 0.010 |
Why?
|
| Acarbose | 1 | 1996 | 10 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1982 | 2509 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1997 | 866 | 0.010 |
Why?
|
| Life Tables | 1 | 1997 | 365 | 0.010 |
Why?
|
| Epidemiologic Factors | 1 | 1996 | 36 | 0.010 |
Why?
|
| Software | 1 | 2010 | 4420 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 4546 | 0.010 |
Why?
|
| Psychometrics | 1 | 2006 | 3049 | 0.010 |
Why?
|
| Health Services Research | 1 | 2004 | 1811 | 0.010 |
Why?
|
| Estradiol | 1 | 2003 | 1932 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 2016 | 15680 | 0.010 |
Why?
|
| Learning | 1 | 1984 | 1733 | 0.010 |
Why?
|
| Birth Weight | 1 | 2003 | 2094 | 0.010 |
Why?
|
| Methods | 1 | 1995 | 1075 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2000 | 882 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 1997 | 998 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 12762 | 0.010 |
Why?
|
| Somatostatin | 1 | 1996 | 447 | 0.010 |
Why?
|
| Folic Acid | 1 | 2001 | 1309 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 7803 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 3804 | 0.010 |
Why?
|
| Research | 1 | 2003 | 1973 | 0.010 |
Why?
|
| Energy Intake | 1 | 2002 | 2128 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 9388 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 20484 | 0.010 |
Why?
|
| Imidazoles | 1 | 1999 | 1178 | 0.010 |
Why?
|
| Employee Performance Appraisal | 1 | 1992 | 86 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 1993 | 451 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1993 | 310 | 0.010 |
Why?
|
| Graves Disease | 1 | 1993 | 239 | 0.010 |
Why?
|
| Anxiety | 1 | 2006 | 4532 | 0.010 |
Why?
|
| Syndrome | 1 | 1997 | 3278 | 0.010 |
Why?
|
| Diabetic Foot | 1 | 1994 | 381 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2004 | 3870 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 1984 | 3976 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1992 | 818 | 0.010 |
Why?
|
| Inservice Training | 1 | 1992 | 376 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1997 | 1920 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1997 | 1805 | 0.010 |
Why?
|
| Leptin | 1 | 1997 | 1590 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 1992 | 344 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 3726 | 0.000 |
Why?
|
| Immunoassay | 1 | 1992 | 748 | 0.000 |
Why?
|
| Confidence Intervals | 1 | 1993 | 2932 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 6543 | 0.000 |
Why?
|
| Insulin Antibodies | 1 | 1985 | 30 | 0.000 |
Why?
|
| Acute Kidney Injury | 1 | 1977 | 1935 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1985 | 645 | 0.000 |
Why?
|
| Glycerol | 1 | 1985 | 277 | 0.000 |
Why?
|
| Mutation | 1 | 2009 | 29950 | 0.000 |
Why?
|
| Phenotype | 1 | 2000 | 16543 | 0.000 |
Why?
|
| Reaction Time | 1 | 1988 | 2075 | 0.000 |
Why?
|
| Health Personnel | 1 | 1995 | 3310 | 0.000 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1993 | 2160 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1993 | 4739 | 0.000 |
Why?
|
| Infant | 1 | 2001 | 36030 | 0.000 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1993 | 3763 | 0.000 |
Why?
|